YolTech Therapeutics Receives FDA Clearance for First Pivotal Trial of In Vivo Gene-Editing Therapy for Primary Hyperoxaluria Type 1
Key Insights
YolTech Therapeutics (search) has received FDA IND clearance to initiate the first pivotal trial of an in vivo gene-editing therapy for Primary Hyperoxaluria Type 1 (search) (PH1 (search)).
YOLT-203 is designed as a once-and-done treatment that targets glycolate oxidase (search) to reduce oxalate overproduction in PH1 (search) patients.
The global multicenter, randomized, double-blind, placebo-controlled study will evaluate safety and efficacy in reducing urinary oxalate levels and improving long-term renal outcomes.
YolTech Therapeutics (search), a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, has received FDA clearance for its Investigational New Drug (IND) application for YOLT-203, marking a significant milestone in the treatment of Primary Hyperoxaluria Type 1 (search) (PH1 (search)). The approval enables the company to proceed with the first pivotal trial of an in vivo gene-editing therapy for this rare genetic disorder.
Breakthrough Gene-Editing Approach
YOLT-203 represents an innovative therapeutic approach designed as a once-and-done treatment for PH1 (search), a rare genetic disorder that leads to recurrent kidney stone (search) formation and progresses to kidney failure (search). The therapy works by deactivating glycolate oxidase (search) (GO (search)), an enzyme encoded by the HAO1 (search) gene, thereby suppressing the synthesis of oxalate precursors and reducing oxalate overproduction in PH1 patients.
The treatment is built on next-generation CRISPR/Cas and lipid nanoparticle (LNP) technologies, positioning it as a potentially transformative one-time intervention with lifelong benefits for patients suffering from this debilitating condition.
Pivotal Trial Design
The upcoming global multicenter, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of YOLT-203 in reducing urinary oxalate levels and improving long-term renal outcomes. This represents the first pivotal trial of an in vivo gene-editing therapy specifically designed for PH1 (search) treatment, highlighting the pioneering nature of this therapeutic approach.
Regulatory Recognition
YOLT-203 has garnered significant regulatory support, receiving Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. FDA, as well as Orphan Drug Designation from the European Medicines Agency (search) (EMA). These designations underscore the therapy's potential to address a significant unmet medical need in the rare disease space.
Company Pipeline and Technology Platform
YolTech Therapeutics (search) is developing an expanding clinical pipeline that targets genetic, metabolic, cardiovascular, and autoimmune diseases. The company's approach focuses on in vivo gene-editing medicines with the potential for one-time, lifelong benefit, with initial results supporting the potential for durable and transformative therapeutic outcomes across multiple disease areas.